Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
TRIFERIC (ferric pyrophosphate citrate) is an intravenous iron replacement therapy administered as a solution for patients with iron deficiency anemia. It delivers bioavailable iron to support hemoglobin synthesis in dialysis-dependent and non-dialysis chronic kidney disease populations. The formulation uses a proprietary citrate-stabilized pyrophosphate complex to optimize iron delivery and tolerability.
Product approaching loss of exclusivity in 2.7 years, with limited commercial team expansion expected; focus shifting toward transition planning and generic defense strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)
Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.
A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients
Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
Worked on TRIFERIC at Rockwell Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
Working on TRIFERIC offers stable manufacturing and operations roles within a niche, specialized therapeutic area with limited but consistent demand. Career growth is constrained by approaching LOE and modest team size, making this suitable for operationally-focused professionals rather than commercial or clinical advancement tracks.
6 open roles linked to this drug